Drug intelligence / Profile preview

3-alpha-sorbithoxyglucose

Development stage: Unknown
Modality: Small Molecules

Overview

3-alpha-sorbithoxyglucose is a novel glycoside isolated from the inner bark of the *Sclerocarya birrea* tree. Identified through phytochemical analysis of dichloromethane-methanol extracts, the compound has demonstrated potential as an antimicrobial agent. In vitro studies have shown minimum inhibitory concentration (MIC) values ranging from 15.625 to 250 μg/mL against a variety of Gram-positive and Gram-negative bacteria, including *Staphylococcus aureus*, *Escherichia coli*, and *Mycobacterium smegmatis*. While it lacks significant cytotoxic effects against breast (MCF7) and prostate (DU145, PC3, LNCaP) cancer cell lines, its antibacterial profile suggests it may serve as a lead for future antimicrobial development.

Other names: 3α-sorbithoxyglucose

Beyond the preview

Go deeper on 3-alpha-sorbithoxyglucose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-alpha-sorbithoxyglucose.

Explore the full profile